---
document_datetime: 2025-12-29 12:16:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/eksunbi.html
document_name: eksunbi.html
version: success
processing_time: 0.109104
conversion_datetime: 2025-12-29 23:05:15.07261
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Eksunbi

[RSS](/en/individual-human-medicine.xml/246167)

##### Withdrawn

This medicine's authorisation has been withdrawn

ustekinumab Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Eksunbi](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 19 August 2025, the European Commission withdrew the marketing authorisation for Eksunbi (ustekinumab) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Samsung Bioepis NL B.V., which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Eksunbi was granted marketing authorisation in the EU on 12 September 2024 for treatment of Crohn's disease, ulcerative colitis, plaque psoriasis, paediatric plaque psoriasis and psoriatic arthritis.  The product had not been marketed in the EU.

Eksunbi was a duplicate application to Pyzchiva which is marketed in several EU countries. The marketing authorisation holder will maintain the marketing authorisation for Pyzchiva.

Eksunbi : EPAR - Medicine overview

Reference Number: EMA/388540/2024

English (EN) (151.21 KB - PDF)

**First published:** 24/09/2024

**Last updated:** 08/09/2025

[View](/en/documents/overview/eksunbi-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-971)

български (BG) (180.46 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/bg/documents/overview/eksunbi-epar-medicine-overview_bg.pdf)

español (ES) (152.53 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/es/documents/overview/eksunbi-epar-medicine-overview_es.pdf)

čeština (CS) (176.2 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/cs/documents/overview/eksunbi-epar-medicine-overview_cs.pdf)

dansk (DA) (151.65 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/da/documents/overview/eksunbi-epar-medicine-overview_da.pdf)

Deutsch (DE) (154.75 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/de/documents/overview/eksunbi-epar-medicine-overview_de.pdf)

eesti keel (ET) (149.54 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/et/documents/overview/eksunbi-epar-medicine-overview_et.pdf)

ελληνικά (EL) (181.71 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/el/documents/overview/eksunbi-epar-medicine-overview_el.pdf)

français (FR) (153.18 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/fr/documents/overview/eksunbi-epar-medicine-overview_fr.pdf)

hrvatski (HR) (172.87 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/hr/documents/overview/eksunbi-epar-medicine-overview_hr.pdf)

italiano (IT) (151.58 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/it/documents/overview/eksunbi-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (182.4 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/lv/documents/overview/eksunbi-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (175.01 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/lt/documents/overview/eksunbi-epar-medicine-overview_lt.pdf)

magyar (HU) (176.41 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/hu/documents/overview/eksunbi-epar-medicine-overview_hu.pdf)

Malti (MT) (176.2 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/mt/documents/overview/eksunbi-epar-medicine-overview_mt.pdf)

Nederlands (NL) (153.01 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/nl/documents/overview/eksunbi-epar-medicine-overview_nl.pdf)

polski (PL) (178.71 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/pl/documents/overview/eksunbi-epar-medicine-overview_pl.pdf)

português (PT) (154.53 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/pt/documents/overview/eksunbi-epar-medicine-overview_pt.pdf)

română (RO) (173.68 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/ro/documents/overview/eksunbi-epar-medicine-overview_ro.pdf)

slovenčina (SK) (178.08 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/sk/documents/overview/eksunbi-epar-medicine-overview_sk.pdf)

slovenščina (SL) (174.13 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/sl/documents/overview/eksunbi-epar-medicine-overview_sl.pdf)

Suomi (FI) (149.74 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/fi/documents/overview/eksunbi-epar-medicine-overview_fi.pdf)

svenska (SV) (151.76 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/sv/documents/overview/eksunbi-epar-medicine-overview_sv.pdf)

Eksunbi : EPAR - Risk management plan

English (EN) (3.77 MB - PDF)

**First published:** 24/09/2024

**Last updated:** 08/09/2025

[View](/en/documents/rmp/eksunbi-epar-risk-management-plan_en.pdf)

## Product information

Eksunbi : EPAR - Product information

English (EN) (1.19 MB - PDF)

**First published:** 24/09/2024

**Last updated:** 08/09/2025

[View](/en/documents/product-information/eksunbi-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-809)

български (BG) (1.28 MB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/bg/documents/product-information/eksunbi-epar-product-information_bg.pdf)

español (ES) (1.05 MB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/es/documents/product-information/eksunbi-epar-product-information_es.pdf)

čeština (CS) (1.09 MB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/cs/documents/product-information/eksunbi-epar-product-information_cs.pdf)

dansk (DA) (1.01 MB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/da/documents/product-information/eksunbi-epar-product-information_da.pdf)

Deutsch (DE) (1.2 MB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/de/documents/product-information/eksunbi-epar-product-information_de.pdf)

eesti keel (ET) (1.1 MB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/et/documents/product-information/eksunbi-epar-product-information_et.pdf)

ελληνικά (EL) (1.3 MB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/el/documents/product-information/eksunbi-epar-product-information_el.pdf)

français (FR) (1.15 MB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/fr/documents/product-information/eksunbi-epar-product-information_fr.pdf)

hrvatski (HR) (1.21 MB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/hr/documents/product-information/eksunbi-epar-product-information_hr.pdf)

íslenska (IS) (1.12 MB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/is/documents/product-information/eksunbi-epar-product-information_is.pdf)

italiano (IT) (1.21 MB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/it/documents/product-information/eksunbi-epar-product-information_it.pdf)

latviešu valoda (LV) (1.22 MB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/lv/documents/product-information/eksunbi-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.23 MB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/lt/documents/product-information/eksunbi-epar-product-information_lt.pdf)

magyar (HU) (1.33 MB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/hu/documents/product-information/eksunbi-epar-product-information_hu.pdf)

Malti (MT) (1.36 MB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/mt/documents/product-information/eksunbi-epar-product-information_mt.pdf)

Nederlands (NL) (1.08 MB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/nl/documents/product-information/eksunbi-epar-product-information_nl.pdf)

norsk (NO) (1.11 MB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/no/documents/product-information/eksunbi-epar-product-information_no.pdf)

polski (PL) (1.14 MB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/pl/documents/product-information/eksunbi-epar-product-information_pl.pdf)

português (PT) (1.2 MB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/pt/documents/product-information/eksunbi-epar-product-information_pt.pdf)

română (RO) (1.35 MB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/ro/documents/product-information/eksunbi-epar-product-information_ro.pdf)

slovenčina (SK) (1.22 MB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/sk/documents/product-information/eksunbi-epar-product-information_sk.pdf)

slovenščina (SL) (1.24 MB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/sl/documents/product-information/eksunbi-epar-product-information_sl.pdf)

Suomi (FI) (1.17 MB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/fi/documents/product-information/eksunbi-epar-product-information_fi.pdf)

svenska (SV) (1.12 MB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/sv/documents/product-information/eksunbi-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000267789 23/05/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Eksunbi : EPAR - All authorised presentations

English (EN) (84.34 KB - PDF)

**First published:** 24/09/2024

**Last updated:** 08/09/2025

[View](/en/documents/all-authorised-presentations/eksunbi-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-683)

български (BG) (92.11 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/bg/documents/all-authorised-presentations/eksunbi-epar-all-authorised-presentations_bg.pdf)

español (ES) (64.33 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/es/documents/all-authorised-presentations/eksunbi-epar-all-authorised-presentations_es.pdf)

čeština (CS) (67.52 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/cs/documents/all-authorised-presentations/eksunbi-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (65.12 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/da/documents/all-authorised-presentations/eksunbi-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (66.44 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/de/documents/all-authorised-presentations/eksunbi-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (63.01 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/et/documents/all-authorised-presentations/eksunbi-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (78.77 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/el/documents/all-authorised-presentations/eksunbi-epar-all-authorised-presentations_el.pdf)

français (FR) (64.37 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/fr/documents/all-authorised-presentations/eksunbi-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (64.6 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/hr/documents/all-authorised-presentations/eksunbi-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (65.84 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/is/documents/all-authorised-presentations/eksunbi-epar-all-authorised-presentations_is.pdf)

italiano (IT) (62.72 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/it/documents/all-authorised-presentations/eksunbi-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (66.64 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/lv/documents/all-authorised-presentations/eksunbi-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (66.45 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/lt/documents/all-authorised-presentations/eksunbi-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (66.94 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/hu/documents/all-authorised-presentations/eksunbi-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (67.31 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/mt/documents/all-authorised-presentations/eksunbi-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (62.33 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/nl/documents/all-authorised-presentations/eksunbi-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (66.74 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/no/documents/all-authorised-presentations/eksunbi-epar-all-authorised-presentations_no.pdf)

polski (PL) (68.18 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/pl/documents/all-authorised-presentations/eksunbi-epar-all-authorised-presentations_pl.pdf)

português (PT) (65.28 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/pt/documents/all-authorised-presentations/eksunbi-epar-all-authorised-presentations_pt.pdf)

română (RO) (65.12 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/ro/documents/all-authorised-presentations/eksunbi-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (68.18 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/sk/documents/all-authorised-presentations/eksunbi-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (64.03 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/sl/documents/all-authorised-presentations/eksunbi-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (63.27 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/fi/documents/all-authorised-presentations/eksunbi-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (63.75 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/09/2025

[View](/sv/documents/all-authorised-presentations/eksunbi-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Eksunbi Active substance ustekinumab International non-proprietary name (INN) or common name ustekinumab Therapeutic area (MeSH)

- Crohn Disease
- Colitis, Ulcerative
- Psoriasis
- Arthritis, Psoriatic

Anatomical therapeutic chemical (ATC) code L04AC05

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

Crohn's Disease Eksunbi is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist or have medical contraindications to such therapies. Ulcerative colitis Eksunbi is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies (see section 5.1). Plaque psoriasis Eksunbi is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate (MTX) or PUVA (psoralen and ultraviolet A) (see section 5.1). Paediatric plaque psoriasis Eksunbi is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies (see section 5.1). Psoriatic arthritis (PsA) Eksunbi, alone or in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate (see section 5.1).

## Authorisation details

EMA product number EMEA/H/C/006448

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

Samsung Bioepis NL B.V.

Olof Palmestraat 10 2616 LR Delft The Netherlands

Opinion adopted 25/07/2024 Marketing authorisation issued 12/09/2024 Withdrawal of marketing authorisation 19/08/2025 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Eksunbi : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (159.05 KB - PDF)

**First published:** 26/05/2025

**Last updated:** 08/09/2025

[View](/en/documents/procedural-steps-after/eksunbi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Eksunbi : EPAR - Procedural steps taken and scientific information after the authorisation (archive)

English (EN) (156.4 KB - PDF)

**First published:** 10/01/2025

**Last updated:** 08/09/2025

[View](/en/documents/procedural-steps-after/eksunbi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Eksunbi : EPAR - Public assessment report

Adopted

Reference Number: EMA/371773/2024

English (EN) (8.33 MB - PDF)

**First published:** 24/09/2024

**Last updated:** 08/09/2025

[View](/en/documents/assessment-report/eksunbi-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Eksunbi

Adopted

Reference Number: EMA/CHMP/322195/2024

English (EN) (177.93 KB - PDF)

**First published:** 26/07/2024

**Last updated:** 08/09/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-eksunbi_en.pdf)

#### News on Eksunbi

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024) 26/07/2024

**This page was last updated on** 08/09/2025

## Share this page

[Back to top](#main-content)